Compare drug alternatives
Segluromet® Alternatives
Segluromet®(metformin hydrochloride) | Steglujan®(ertugliflozin / sitagliptin) |
---|---|
Prescription Only | Prescription Only |
Dosage & Administration | |
Administration | |
Oral . Learn more. | Oral . Learn more. |
Dosing | |
Maximum recommended dose is 7.5 mg ertugliflozin/1,000 mg metformin twice daily. Take twice daily with meals, with gradual dose escalation. Do not use in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2 . . Learn more. | Recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily, taken in the morning, with or without food. Increase dose to 15 mg ertugliflozin/100 mg sitagliptin once daily in those tolerating STEGLUJAN for additional glycemic control. . Learn more. |
Latin Shorthand | |
Max dose: 7.5 mg ertugliflozin / 1000 mg metformin BID. Take with meals, gradual dose increase. Avoid if eGFR < 30 mL/min/1.73 m².. Learn more. | 5 mg ertugliflozin/100 mg sitagliptin qd in AM, with or without food. Increase to 15 mg ertugliflozin/100 mg sitagliptin qd for those tolerating STEGLUJAN and needing additional glycemic control.. Learn more. |
Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $0. Learn more. |
Annual Cap | |
$583 per fill . Learn more. | $583 per fill . Learn more. |
Assistance Expiration | |
12 uses. Learn more. | 12 uses. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
Physician Advisory | |
Adverse Reactions | |
Most common adverse reactions associated with ertugliflozin
(incidence ≥5%) were female genital mycotic infections.
Most common adverse reactions associated with metformin
(incidence ≥5%) were diarrhea, nausea, vomiting, flatulence,
abdominal discomfort, indigestion, asthenia, and headache. . Learn more. | Most common adverse reactions associated with ertugliflozin
(incidence ≥5%): female genital mycotic infections.
Most common adverse reactions associated with sitagliptin
(incidence ≥5%): upper respiratory tract infection, nasopharyngitis
and headache. In the add-on to sulfonylurea and add-on to insulin
studies, hypoglycemia was also more commonly reported in patients
treated with sitagliptin compared to placebo.. Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | SGLT2 Inhibitors. Learn more. |
Special Populations | |
Popular Alternatives
- Segluromet® vs Victoza®
- Segluromet® vs Trulicity®
- Segluromet® vs Xultophy®
- Segluromet® vs Soliqua®
- Segluromet® vs Ozempic®
- Segluromet® vs Rybelsus®
- Segluromet® vs Mounjaro®
- Segluromet® vs Bydureon®
- Segluromet® vs Invokamet®
- Segluromet® vs Invokamet®
- Segluromet® vs Invokana®
- Segluromet® vs Farxiga®
- Segluromet® vs Glyxambi®
- Segluromet® vs Jardiance®
- Segluromet® vs Synjardy®
- Segluromet® vs Trijardy XR®
- Segluromet® vs Steglatro®
- Segluromet® vs Inpefa®